Clinical Trials Directory

Trials / Completed

CompletedNCT01704547

Breast Cup Immobilization Device II (GCC 1047)

Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II

Status
Completed
Phase
Study type
Observational
Enrollment
25 (actual)
Sponsor
University of Maryland, Baltimore · Academic / Other
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study is designed to assess the accuracy of patient breast reproducibly using the revised BCID. This study would provide data for target verification and quality assurance to eventually allow treatment of breast cancer patients for either a TBB or accelerated partial breast irradiation. The BCID is a low-risk device similar to immobilization devices used routinely in radiotherapy for other disease sites.

Detailed description

Breast conserving therapy (BCT) has become the standard of care for treating early-stage breast cancers based on six prospective randomized trials with 20 years of follow-up data (Fisher). During lumpectomy, the surgeon removes the tumor and a surrounding rim of normal tissue (margin), leaving surgical clips to help designate the resection bed. Radiation treatment is directed at the whole breast for 5 1/2 weeks and is generally followed by a 1-2 week boost directed at the lumpectomy site plus a margin of normal breast tissue. The benefit of adding the tumor bed boost, (TBB) has been shown in two studies to decrease local failures \[Romestaig; Bartelink\]. Studies have evaluated the role of radiation following lumpectomy in very select groups which have not been able to define a group who do not benefit from the addition of radiotherapy. In the group of patients who received surgery alone, 85% of the breast recurrences occurred in the tumor bed. Due to these two facts, radiotherapy directed only at the tumor bed has been evaluated. Treating this smaller tumor volume has allowed higher doses of radiation to be delivered safely shortening the treatment course from 6-7 weeks to one week.

Conditions

Timeline

Start date
2012-10-01
Primary completion
2016-03-01
Completion
2016-03-01
First posted
2012-10-11
Last updated
2023-02-01
Results posted
2023-02-01

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01704547. Inclusion in this directory is not an endorsement.